Moderna Inc. (MRNA) Stock

NASDAQ
HealthcareBiotechnology Website

MRNA has an Alpha Score of 35 out of 100 (weak), computed on Nov 21, 2026 from 2 of 4 sub-scores. 7 members of Congress disclosed 23 trades in MRNA since 2021: 7 purchases and 16 sales, most recently Gilbert Cisneros (purchase, Oct 20, 2026). 6 of the hedge funds AlphaScala tracks reported MRNA in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $749.84M. Company insiders reported 0 open-market buys and 12 sales on SEC Form 4 in the 90 days to Nov 20, 2026.

$195.00
-2.17%
Daily close on Nov 20, 2026
Source: TwelveData
Alpha Score
35
Weak

What is MRNA's Alpha Score?

How it works →

Alpha Score of 35 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.

Momentum
54
Weak
Quality
40
Weak

Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Moderna Inc. (MRNA)?

Members
7
Disclosed trades
23
Purchases
7
Sales
16

Most recent: Gilbert Cisneros (purchase, Oct 20, 2026); records start Jan 8, 2021.

PoliticianTrade dateTypeAmount
Gil Cisneros
D-CA · House
2026-10-20purchase$1k – $15k
Maria Elvira Salazar
R-FL · House
2026-09-24partial sale$1k – $15k
Maria Elvira Salazar
R-FL · House
2026-08-19partial sale$1k – $15k
Maria Elvira Salazar
R-FL · House
2026-08-19purchase$1k – $15k
Rob Bresnahan
R-PA · House
2025-04-08sale$1k – $15k
Rob Bresnahan
R-PA · House
2025-02-25purchase$1k – $15k
Julie Johnson
D-TX · House
2025-01-15sale$1k – $15k
Josh Gottheimer
D-NJ · House
2024-02-01sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

See all MRNA political trades →

Which hedge funds own MRNA?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Millennium Management
Israel Englander
3.89M$749.84M+788%
Citadel
Ken Griffin
116K$22.37M-61%
Point72
Steve Cohen
109K$20.92MNEW
Bridgewater Associates
Ray Dalio
72K$13.93M+528%
D.E. Shaw
David Shaw
26K$5.04M+5%
Hussman Investment Trust
John Hussman
6K$1.21MNEW

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Moderna Inc. insiders buying or selling?

SEC Form 4 filings
90 days to Nov 20, 2026
Buys
0
Sells
12
Net $
-$50.8M
Unique insiders
3
DateInsiderRoleTypeSharesValue
Nov 17, 26Hoge StephenPresidentSELL34.0K$7.2M
Nov 17, 26Hoge StephenPresidentSELL5.1K$1.1M
Nov 17, 26Hoge StephenPresidentSELL157$34K
Nov 16, 26Hoge StephenPresidentSELL39.2K$8.6M
Oct 15, 26Hoge StephenPresidentSELL39.1K$8.6M
Oct 14, 26Hoge StephenPresidentSELL38.8K$8.3M
Oct 14, 26Hoge StephenPresidentSELL450$96K
Sep 15, 26Hoge StephenPresidentSELL40.3K$5.9M
Sep 14, 26Hoge StephenPresidentSELL40.3K$5.8M
Sep 10, 26Mock James MChief Financial OfficerSELL19.8K$2.7M

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are MRNA's key statistics?

EPS (TTM)
-7.10
Beta
1.23
Net Margin
-110.46%
ROE
-37.62%
Debt / Equity
0.07
52W High
$280.80
52W Low
$22.28

Key statistics as of Nov 11, 2026

How does MRNA's valuation compare with the Healthcare sector?

MetricMRNAHealthcare medianCompanies in median
Net margin-110.46%3.62%218
Return on equity-37.62%3.50%249

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 21, 2026). P/E excludes loss-making companies.

AlphaScala analysis on MRNA

Latest 1

MRNA price chart

Powered by TradingView

What does Moderna Inc. do?

Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary function centers on creating innovative therapeutics and vaccines using mRNA technology, targeting a broad spectrum of diseases including infectious, oncological, rare, and cardiovascular conditions. Key products include Spikevax, an mRNA-based COVID-19 vaccine, alongside mRESVIA for respiratory syncytial virus (RSV), and investigational vaccines for seasonal influenza, cytomegalovirus, Epstein-Barr virus, norovirus, Zika, and bacterial diseases like Lyme. In oncology, it advances individualized neoantigen therapies and immune modulation treatments; for rare diseases, it develops therapies for propionic acidemia, glycogen storage disease, and cystic fibrosis. With a pipeline of over 40 clinical-stage products, Moderna, Inc. plays a pivotal role in the biopharmaceutical sector, driving advancements in precision medicine and public health responses to pandemics and endemic threats through its mRNA platform.

CEO
Mr. Stéphane Bancel M.B.A.
Employees
4,700
Market Cap
$102.18B
Ask about MRNAAI research agent